Vyanka Redenbaugh, MD, Mayo Clinic College of Medicine, Rochester, MN, discusses the current criteria for diagnosing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Dr Redenbaugh affirms that these criteria have proven beneficial, particularly in identifying isolated positives in CSF. A notable point is the discussion against the possibility of MOGAD in the absence of MOG-IgG, reinforcing that the presence of the antibody is crucial for the diagnosis. Furthermore, an intriguing aspect being explored is the rapid resolution of MRI lesions in MOGAD. This phenomenon, distinct from the patterns seen in diseases like multiple sclerosis or aquaporin-4 NMOSD, offers potential for differentiating these conditions. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.